Hemosol B0

Hemosol B0 is a sterile solution for injection that contains calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied as an electrolyte solution intended for use in haemodialysis or intravenous administration. The product is manufactured for the European market and is classified as a prescription‑only renal replacement therapy agent. It provides essential electrolytes and a bicarbonate buffer to help maintain acid‑base balance during treatment.

Hemosol B0 is employed in clinical settings where rapid correction of electrolyte and acid‑base disturbances is required.

- Hemodialysis procedures to replace lost electrolytes and maintain plasma bicarbonate. - Acute renal failure management when renal excretion of electrolytes is impaired. - Intravenous electrolyte replacement in patients with severe fluid and electrolyte losses. - Support of metabolic acidosis correction during renal replacement therapy. - Peri‑operative fluid management in surgeries with anticipated electrolyte shifts.

Adverse reactions to Hemosol B0 are generally infrequent, but they may vary in severity.

Common: - Mild nausea or vomiting. - Transient headache. - Localized infusion site irritation or erythema. - Slight increase in serum calcium or magnesium levels without clinical symptoms.

Serious: - Severe hyperkalemia or hypermagnesemia leading to cardiac arrhythmia. - Acute pulmonary edema from fluid overload. - Anaphylactic or severe hypersensitivity reaction. - Significant metabolic alkalosis requiring medical intervention.

When using Hemosol B0, clinicians should observe specific precautions to minimize risk.

- Assess baseline electrolyte and acid‑base status before initiation. - Monitor serum calcium, magnesium, sodium, and bicarbonate levels regularly during therapy. - Adjust infusion rate in patients with compromised cardiac function or fluid overload risk. - Use caution in pregnant or lactating women; safety data are limited. - Avoid rapid administration that may cause sudden shifts in plasma osmolality. - Ensure compatibility with other intravenous solutions to prevent precipitation.

Hemosol B0 may interact with certain medications or solutions; awareness of these interactions helps maintain safety.

Avoid: - Concurrent use of calcium channel blockers that may exacerbate hypercalcemia. - High‑dose magnesium sulfate infusions, which can lead to additive hypermagnesemia. - Sodium‑containing medications that could precipitate fluid overload.

Use with caution: - Loop diuretics, as they may alter electrolyte balance and require dose adjustments. - ACE inhibitors or ARBs, which affect renal handling of electrolytes. - Blood products or albumin solutions, requiring monitoring for electrolyte shifts.